Skip to main content

A phase II trial of neoadjuvant gemcitabine/nab-paclitaxel and SBRT for potentially resectable pancreas cancer: An evaluation of acute toxicity.

Publication ,  Conference
Palta, M; Czito, BG; Duffy, E; Malicki, M; Niedzwiecki, D; Abbruzzese, JL; Uronis, HE; Blobe, GC; Blazer, DG; Willett, C
Published in: Journal of Clinical Oncology
May 20, 2018

Duke Scholars

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2018

Volume

36

Issue

15_suppl

Start / End Page

4121 / 4121

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Palta, M., Czito, B. G., Duffy, E., Malicki, M., Niedzwiecki, D., Abbruzzese, J. L., … Willett, C. (2018). A phase II trial of neoadjuvant gemcitabine/nab-paclitaxel and SBRT for potentially resectable pancreas cancer: An evaluation of acute toxicity. In Journal of Clinical Oncology (Vol. 36, pp. 4121–4121). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.4121

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2018

Volume

36

Issue

15_suppl

Start / End Page

4121 / 4121

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences